MDXGMiMedx Group, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.
Priced for ~2% a year FCF growth. The price demands less than its three-year revenue growth of 6% a year, expectations look modest.
Expensive vs its own history: P/E 115.3 vs a 29.1 median over 17 quarters (+296% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What MDXG's price assumes
MiMedx Group, Inc. trades at 115× earnings against 18.6× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.6 · 6.21× the median: the market pays up for this one
- Price / sales
- 1.51
Price / sales · as of 2026-Q1
- Free cash flow yield
- 6.5%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +2.2%
Growth the price implies · The price pays for +2.2% free cash flow growth a year for a decade; revenue has grown +6.4% a year over the last three.
Details›
- Price / bookas of 2026-Q1
- 2.42
- EV / EBIToperating margin 2.5%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 1.15
- Healthcare median P/E509 names
- 26.0
- Biotechnology median P/E244 names
- 18.6
- Free cash flow, trailing twelve months
- $45M
- Market capitalisation
- $687M
- 3-year revenue growth
- +6.4%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 115× today against a 29.1× median |
| 52-week range | $3.09 – $7.96 |
| Today | $4.61 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.